Lorvotuzumab mertansine
As of the edition of 20 October 2026, Lorvotuzumab mertansine is an antibody drug conjugate: went quiet in 2021; acts on NCAM1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Antibody drug conjugate
- Registered trials
- 7, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Heart and blood vessels; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lorvotuzumab mertansine.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NCAM1 | Neural cell adhesion molecule 1 | P13591 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| ImmunoGen | Lead sponsor of trials | 2002 to now |